•  
  •  
  •  
  •  

2023-03-24 01:37:15

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • W S Industries India Ltd approves availing of short term loans
  • SBI completes acquisition of 40% stake of Canara Bank in Commercial Indo Bank LLC
  • Indigenous Casting Technology Pvt Ltd becomes 100% subsidiary of NIBE Ltd
  • R.P.P Infra Projects Wins a New Order Worth INR 104.79 Crores
  • Healthcare Triangle to Participate in ViVE 2023 as Presenter and Sponsor

Keywords Selected:  ShilpaMedicare

IPO News

  • Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

  • Shilpa Medicare Ltd gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
  • Shilpa Medicare Ltd registers Bengaluru facility with Ministry of Health, UAE
  • Shilpa Medicare Ltd launches Capecitabine 1000 MG dispersible tablet
  • Shilpa Medicare Ltd's Unit IV, Jadcherla, Telangana facility has received Health Canada GMP Approval
  • Shilpa Medicare Ltd, Analytical Services Division, Nacharam, Hyderabad, Telangana receives EIR
  • Shilpa Medicare Ltd receives tentative approval from USFDA for Tenofovir Alafenamide Tablets
  • Shilpa Medicare completes Human Clinical Studies of High Concentration Biosimilar Adalimumab
  • ShilpaMedicare Ltd Q1FY23 consolidated PAT slumps QoQ to Rs. 84.85 lakhs
  • Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA Remote Record Review
  • Shilpa Medicare Limited, Unit 1, Raichur API facility receives Russian GMP
  • Shilpa Medicare Limited, Unit VI, Bengaluru facility has been issued UK MHRA GMP
  • Shilpa Meidcare Ltd consolidated Q4FY22 PAT jumps to Rs. 29.54 crores
  • Shilpa Medicare Ltd recommends dividend of Rs. 1.10
  • US FDA Inspection of Shilpa Medicare Limited, Unit VII, Analytical Services Division
  • Shilpa Medicare receives NoC from RCGM, Dept. of Biotechnology for its Biosimilar Aflibercept
  • Shilpa Biologicals partners with Mylab
  • Shilpa Medicare posts consolidated Q3FY22 net profit of Rs. 9.56 crores
  • Shilpa Medicare receives approval in Europe for Pemetrexed Injection
  • Shilpa Medicare Limited launches PRUCALSHIL (Prucalopride) Orally Disintegrating Strips 1 Mg And 2 Mg in India
  • US FDA concludes remote record review of Unit 3 of Shilpa Medicare Ltd
  • Shilpa Medicare Ltd enters Phase I Clinical Trial for its New Biological Entity, recombinant Human Albumin
  • Shilpa Medicare Ltd Q2FY22 consolidated net profit at Rs. 19.88 crore
  • Shilpa Medicare raises over Rs. 297 crore from marquee investors
  • Shilpa Medicare Limited approves preferential allotment to investors

Latest Post

  • W S Industries India Ltd approves availing of short term loans
  • SBI completes acquisition of 40% stake of Canara Bank in Commercial Indo Bank LLC
  • Indigenous Casting Technology Pvt Ltd becomes 100% subsidiary of NIBE Ltd
  • R.P.P Infra Projects Wins a New Order Worth INR 104.79 Crores
  • Healthcare Triangle to Participate in ViVE 2023 as Presenter and Sponsor


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022